公开(公告)号：US20150083664A1

公开(公告)日：2015-03-26

申请号：US14507597

申请日：2014-10-06

申请人： Advanced Renal Technologies

发明人： Robin Callan ,  James J. Cole

IPC分类号： A61M1/16

CPC分类号： A61M1/1654 ,  A61K31/19 ,  A61K31/191 ,  A61K33/10 ,  A61K33/14 ,  A61M1/3672 ,  A61M1/3675 ,  A61M2202/0413 ,  A61K2300/00

摘要： The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p

摘要翻译： 尿素清除方面的透析剂量在许多血液透析患者中​​是微不足道的，而通过透析前血清HCO3水平测定的代谢性酸中毒是常见的。 包含柠檬酸而不是乙酸作为酸化剂的透析液提供优异的性能。 含有柠檬酸盐的透析液仅用于22例血液透析患者。 最初，22例患者中只有8例血液中HCO3> 23mEq / L（正常值下限），然而，使用柠檬酸盐透析液透析12周后，血清HCO3在15例患者（p = 0.0001，卡方）。 在19例患者中透析变量保持不变，他们也使用和重复使用相同的透析器模型。 在这些患者中，初始平均尿素减少率（URR）为68.5±5.9％，用本文公开的柠檬酸盐透析液处理后，该比例增加至73±5.3％（p <0.03）。 使用Daugirdas II公式计算的SpKt / V也从1.23±0.19增加到1.34±0.2（p = 0.01）。 这种增加的尿素清除可能是柠檬酸盐维持透析膜通畅的抗凝血性能的结果。 透析前血清HCO3的增加可能代表来自透析液的增加的递送和柠檬酸的产生。

公开(公告)号：US20150024068A1

公开(公告)日：2015-01-22

申请号：US14383178

申请日：2013-03-05

申请人： GAMBRO LUNDIA AB

发明人： Anders Nilsson ,  Jan Sternby ,  Anders Wieslander

IPC分类号： A61K31/194 ,  A61K33/06

CPC分类号： A61K9/08 ,  A61K31/194 ,  A61K33/06 ,  A61K33/14 ,  A61M1/1654 ,  A61K2300/00

摘要： Dialysis fluid compositions including 0.5 to 3 mM citrate, 1 to 5 mM total calcium, and 0 to 1.5 mM total magnesium. These dialysis fluid compositions include 0.10 to 0.2 mM more total calcium per 1 mM citrate within the dialysis fluid as compared to the calcium concentration ordinarily prescribed for a non-citrate containing dialysis fluid.

摘要翻译： 包含0.5至3mM柠檬酸盐，1至5mM总钙和0至1.5mM总镁的透析液组合物。 与通常对含有非柠檬酸盐的透析液所规定的钙浓度相比，这些透析液组合物在透析液中含有每1mM柠檬酸盐更多的总钙0.10〜0.2mM。

公开(公告)号：US20140335198A1

公开(公告)日：2014-11-13

申请号：US14272026

申请日：2014-05-07

申请人： National University Corporation Chiba University ,  Fuso Pharmaceutical Industries, Ltd.

发明人： Shigeto ODA ,  Tomohito SADAHIRO ,  Masataka NAKAMURA ,  Syuichi TANAKA ,  Shogo TOKUOKA ,  Hiroya OTANI

IPC分类号： A61K33/42 ,  B65D81/32 ,  A61K31/7004 ,  A61M1/16 ,  A61K33/14 ,  A61K33/10

CPC分类号： A61K33/42 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/7004 ,  A61K33/06 ,  A61K33/10 ,  A61K33/14 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61M1/1654 ,  B65D81/3261 ,  A61K2300/00

摘要： The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemeia and hypophosphatemia are not caused.

摘要翻译： 本发明涉及一种稳定的含碳酸氢根离子的药物溶液，特别是一种用于透析的含碳酸氢盐的药物溶液，其中稳定性已通过存在磷酸根离子而得到改善。 此外，本发明涉及用于急性血液净化的药物溶液，特别是在含有药物溶液的使用前混合的透析液和急性血液净化用替代液。 此外，本发明涉及一种透析液和用于急性血液净化的替代液体，其在使用之前混合，其中混合后长时间防止形成不溶性细颗粒或沉淀物，并且不引起低钾血症和低血糖症。

公开(公告)号：US20140319030A1

公开(公告)日：2014-10-30

申请号：US14269602

申请日：2014-05-05

申请人： Baxter International Inc. ,  Baxter Healthcare S.A.

发明人： Dilip H. Shah ,  Todd Ing

IPC分类号： A61K31/19

CPC分类号： A61M1/1654 ,  A61K31/19 ,  A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  A61K2300/00 ,  A61M1/1656 ,  A61M1/1666 ,  A61M5/16827 ,  Y10T137/2499

摘要： The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

摘要翻译： 本发明构成适于用于制备用于批量和/或配制系统的透析液的透析液制剂，并且通过减少或防止透析流道的凝结来改善透析效率。 用于一批透析液的透析液化学制剂包含存储在第一容器中的酸浓缩物和存储在第二容器中的含柠檬酸盐的碳酸氢盐浓缩物。 将第一和第二容器的内容物倒入透析液制备罐中并与水混合以形成一批量的透析液。 或者，将干酸和/或含柠檬酸枸橼酸盐的浓缩物分别溶解在测量量的水中以形成液体浓缩物，然后将其与配比机联合使用以在线生成最终透析溶液流。

公开(公告)号：US08864699B2

公开(公告)日：2014-10-21

申请号：US12973598

申请日：2010-12-20

申请人： Robin Callan ,  James J. Cole

发明人： Robin Callan ,  James J. Cole

IPC分类号： A61M37/00 ,  A61M1/36 ,  A61K33/10 ,  A61K31/19 ,  A61M1/16 ,  A61K33/14 ,  A61K31/191

CPC分类号： A61M1/1654 ,  A61K31/19 ,  A61K31/191 ,  A61K33/10 ,  A61K33/14 ,  A61M1/3672 ,  A61M1/3675 ,  A61M2202/0413 ,  A61K2300/00

摘要： The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p

摘要翻译： 尿素清除方面的透析剂量在许多血液透析患者中​​是微不足道的，而通过透析前血清HCO3水平测定的代谢性酸中毒是常见的。 包含柠檬酸而不是乙酸作为酸化剂的透析液提供优异的性能。 含有柠檬酸盐的透析液仅用于22例血液透析患者。 最初，22例患者中只有8例血液中HCO3> 23mEq / L（正常值下限），然而，使用柠檬酸盐透析液透析12周后，血清HCO3在15例患者（p = 0.0001，卡方）。 在19例患者中透析变量保持不变，他们也使用和重复使用相同的透析器模型。 在这些患者中，初始平均尿素减少率（URR）为68.5±5.9％，用本文公开的柠檬酸盐透析液处理后，该比例增加至73±5.3％（p <0.03）。 使用Daugirdas II公式计算的SpKt / V也从1.23±0.19增加到1.34±0.2（p = 0.01）。 这种增加的尿素清除可能是柠檬酸盐维持透析膜通畅的抗凝血性能的结果。 透析前血清HCO3的增加可能代表来自透析液的增加的递送和柠檬酸的产生。

公开(公告)号：US20140224737A1

公开(公告)日：2014-08-14

申请号：US14178677

申请日：2014-02-12

申请人： FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

发明人： Thomas FICHERT ,  INGO BICHLMAIER

IPC分类号： A61M1/16

CPC分类号： A61M1/1654 ,  A61K31/74 ,  A61K45/06 ,  A61M1/287 ,  B01J20/268 ,  Y10T428/24802 ,  A61K2300/00

摘要： The present invention relates to polymers imprinted by retention solutes, use of same as well as compositions containing same.

摘要翻译： 本发明涉及由保留溶质印制的聚合物，其使用方法以及含有它们的组合物。

公开(公告)号：US20130186829A1

公开(公告)日：2013-07-25

申请号：US13789391

申请日：2013-03-07

申请人： Advanced Renal Technologies

发明人： Robin Callan ,  Walter A. Van Schalkwijk ,  James J. Cole

IPC分类号： A61M1/16

CPC分类号： A61M1/287 ,  A61K31/19 ,  A61K31/194 ,  A61K31/7004 ,  A61K33/00 ,  A61K33/14 ,  A61K33/26 ,  A61K45/06 ,  A61M1/1654 ,  A61M1/1656 ,  A61M1/1666 ,  A61M1/1672 ,  A61K2300/00

摘要： Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

公开(公告)号：US20130077783A1

公开(公告)日：2013-03-28

申请号：US13673461

申请日：2012-11-09

申请人： SecureRF Corporation

发明人： Iris Anshel ,  Michael Anshel ,  Dorian Goldfeld

IPC分类号： H04L9/08

CPC分类号： A61K33/14 ,  A61K9/08 ,  A61K31/194 ,  A61K31/7004 ,  A61K33/00 ,  A61K33/06 ,  A61M1/14 ,  A61M1/1654 ,  H04L9/0841 ,  H04L9/0861 ,  H04L9/0869 ,  H04L9/14 ,  H04L9/30 ,  H04L9/3013 ,  H04L63/0428 ,  H04L2209/12

摘要： A system and method for generating a secret key to facilitate secure communications between users. A first and second and a function between the two monoids are selected, the function being a monoid homomorphism. A group and a group action of the group on the first monoid is selected. Each user is assigned a submonoid of the first monoid so that these submonoids satisfy a special symmetry property determined by the function, a structure of the first and second monoids, and the action of the group. A multiplication of an element in the second monoid and an element in the first monoid is obtained by combining the group action and the monoid homomorphism. First and second users choose private keys which are sequences of elements in their respective submonoids. A first result is obtained by multiplying an identity element by the first element of the sequence in a respective submonoid. Starting with the first result, each element of the user's private key may be iteratively multiplied by the previous result to produce a public key. Public keys are exchanged between first and second users. Each user's private key may be iteratively multiplied by the other user's public key to produce a secret key. Secure communication may then occur between the first and second user using the secret key.

公开(公告)号：US20110237996A1

公开(公告)日：2011-09-29

申请号：US12817390

申请日：2010-06-17

申请人： Peter Kotanko ,  Stephan Thijssen ,  Nathan W. Levin

发明人： Peter Kotanko ,  Stephan Thijssen ,  Nathan W. Levin

IPC分类号： A61M1/16

CPC分类号： A61M1/3458 ,  A61M1/16 ,  A61M1/1613 ,  A61M1/1654 ,  A61M1/1656 ,  A61M1/3672 ,  A61M1/3675 ,  A61M2230/20

摘要： A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration. The method can further include statistically correcting the preliminary predicted systemic ionized calcium concentration for any time point during the dialysis treatment to provide a final predicted systemic ionized calcium concentration for that time point.

摘要翻译： 执行患者血液的区域性柠檬酸盐抗凝剂透析的方法包括通过包括具有半透性透析膜的透析器和围绕膜的透析液室的体外回路流动患者的血液并返回到患者。 该方法还包括使含有钙和柠檬酸盐的透析液流过透析器的透析液室，并将柠檬酸盐引入到透析器上游的患者血液中，从而透析患者的血液。 该方法还可以包括例如通过数学模型来预测透析治疗或透析后任何时刻患者血液中全身电离钙的浓度。 该方法可进一步包括统计校正患者血液中全身电离钙的初步预测的透析后浓度，以提供最终预测的透析后全身电离钙浓度。 该方法还可以包括在透析治疗期间的任何时间点统计地校正初步预测的全身电离钙浓度，以在该时间点提供最终预测的全身电离钙浓度。

公开(公告)号：US20110079558A1

公开(公告)日：2011-04-07

申请号：US12896009

申请日：2010-10-01

申请人： Jochen G. Raimann ,  Erik Lars Penne ,  Stephan Thijssen ,  Peter Kotanko ,  Nathan W. Levin

发明人： Jochen G. Raimann ,  Erik Lars Penne ,  Stephan Thijssen ,  Peter Kotanko ,  Nathan W. Levin

IPC分类号： B01D61/32

CPC分类号： A61M1/1654 ,  A61M1/1613 ,  A61M2205/52

摘要： A method of controlling diffusive sodium transport from the dialysate solution to the blood of a patient undergoing hemodialysis treatment or from the blood to the dialysate solution includes calculating SNa+average, an average of the patient's historic serum sodium concentrations, and estimating SNa+estimated, the patient's pre-dialysis serum sodium concentration, based on the average of the patient's measured historic pre-dialysis serum sodium concentrations, SNa+measured. The method enables adjusting DNa+, the sodium concentration of the dialysate solution, based on the average of the patient's historic serum sodium concentrations, SNa+average, if needed, and performing the dialysis treatment of the patient using a dialysate solution containing a sodium concentration DNa+.

摘要翻译： 控制从透析液向经血液透析治疗的患者或从血液到透析液的血液的扩散钠转运的方法包括计算SNa +平均值，患者血清钠浓度的平均值，估计SNa + 患者的透析前血钠浓度，根据患者血清钠浓度测定历史透析前平均值，测定SNa +。 该方法可以根据患者历史血清钠浓度，SNa +平均值（如果需要）的平均值调整DNa +，透析液溶液的钠浓度，并使用含有钠浓度DNa +的透析液进行患者的透析治疗， 。